Skip to main content

Digital Droplet PCR Assay to Measure AAV vector DNA

Droplet digital PCR (ddPCR):
A third generation of quantitative PCR, water and oil emulsions is used to segment the samples and create droplets to identify and quantify the genetic material in the sample. It is a new PCR technique that directly quantifies DNA copies with an unparalleled degree of precision and without the need for a standard curve or for a high degree of amplification efficiency; all properties that lend themselves to the accurate quantification of both single-stranded and self-complementary AAV genomes.

The advantage of ddPCR for the nucleic acid quantification includes: 
  • Unparalleled precision: the massive sample partitioning afforded by ddPCR enables small fold decrease in target DNA sequences between samples to be reliably measured.  
  • Increased signal-to-noise: enrich for rare targets by reducing competition that comes from high-copy templates. 
  • Removal of PCR efficiency bias: error rates are reduced by removing the amplification efficiency reliance of PCR, enabling accurate quantification of targets.
  • Simplified quantification: a standard curve is not required for absolute quantification
The procedure/steps involved for quantification of viral DNA using Bio-rad's ddPCR are:
i) Droplet Generation 
ii) PCR Amplification
iii) Droplet Reading 
iv) ddPCR Data Analysis 



i) Droplet Generation
Before droplet generation, ddPCR reaction are prepared in a similar manner as read-time PCR reactions that use Taq man hydrolysis probes labeled with FAM and HEX (or VIC) reporter flurophores, or an intercalating dye such as EvaGreen.
  • For the droplet generation, assemble the recommended ddPCR supermix (Bio-Rad, Hercules, CA) for preparing the reaction mixtures. 
  • Use the pre-designed TaqMan primers and probes in final optimized concentrations of (~100 nM to 100 nM), and template (5 μl) in a final volume of 20 μl. 
  • Load each reaction into the sample well of an eight-well disposable cartridge (Bio-Rad) along with 70 μl of droplet generation oil (Bio-Rad), and generate droplets in a droplet generator (Bio-Rad). 
  • The droplet generator produces about 20,000 droplets per sample in about 2.5 min for eight samples. 
ii) PCR Amplification
  • Gently pipette and transfer droplets to a 96-well PCR plate and seal the plate with PCR plate sealer and pierceable foil heat seal
  • Amplify the DNA to the end point with a conventional thermal cycler with recommended cycling protocol (95°C for 10 min, followed by 42 cycles of 95°C for 30 sec, 60°C for 1 min, and 72°C for 15 sec followed by a final 98°C heat treatment for 10 min).
iii) Droplet Reading
  • Open the QuantaSoft software in the setup mode and design a new plate with a layout according to the experimental design.
  • Designate the sample name, experiment type, corresponding fluorescence channels such as FAM and HEX.
  • Scan the PCR plate on QX100 droplet reader (Bio-Rad).

iv) ddPCR Data Analysis 
  • Analyze the data with QuantaSoft software.
  • If the plate is set up for absolute quantitation analysis, automatic thresholding determines concentration and populates the data tables in the analysis mode of the software. 
  • The concentration reported is coplies per microliter of the final 1X ddPCR reaction. 
  • The copies per microliter readout from the QX100 reader should be converted to genome copies per milliliter according to the formula:
X=[(aY)(1000/b)]D,
        where X is GC/ml, a is volume of the ddPCR (20 μl),
        Y is ddPCR readout copies per microliter, 
        b is volume of diluted vector in the ddPCR (5 μl), and 
        D is total dilution applied to the test material.



References:
Primer and Probe designing for ddPCR/qPCR
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991984/
https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6407.pdf
Labels:

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more

Cell-Mediated Immunity in AAV Gene Therapy

Cell-mediated immunity (CMI) plays a significant role in the effectiveness and safety of AAV (Adeno-Associated Virus) gene therapy. Understanding the impact of CMI is crucial for optimizing therapeutic outcomes and managing potential adverse effects. Here’s a detailed overview of the impact of CMI on AAV gene therapy: 1. Mechanisms of Cell-Mediated Immunity in AAV Gene Therapy T-Cell Activation : After administration of an AAV vector, T cells can recognize the AAV capsid proteins or the transgene product as foreign antigens, leading to their activation. This can involve both CD4+ helper T cells and CD8+ cytotoxic T cells. Cytokine Production : Activated T cells produce cytokines (e.g., IFN-γ, TNF-α) that can enhance the immune response. These cytokines can influence the activation and proliferation of other immune cells, including B cells and macrophages. 2. Impact on Efficacy of AAV Gene Therapy Enhanced Antigen Presentation : CMI can improve the presentation of transgene-derived anti...
Read more

Preclinical Studies for AAV Gene Therapy

 Preclinical studies for AAV gene therapy are crucial to assess the safety, efficacy, biodistribution, and immunogenicity of the therapy before progressing to human trials. These studies help in understanding the potential risks and therapeutic effects in animal models, which is essential for regulatory approval to proceed to first-in-human studies. Here’s a breakdown of key preclinical study types and their objectives: 1. Efficacy Studies Objective : Determine whether the gene therapy delivers a therapeutic benefit in relevant disease models, such as improvement in phenotypic markers or functional outcomes. Study Design : Use disease-specific animal models that reflect the condition the therapy intends to treat (e.g., knockout models for genetic disorders). Evaluate therapeutic endpoints, such as protein expression, functional assays, or phenotypic changes. Example : For a neurological condition, measure motor function or cognitive outcomes in treated versus control groups. 2. Bio...
Read more